IGF1R and glioblastoma: Targeting of the IGF-1R/PI3K signaling in GBM cells using the IGF-1R inhibitor OSI906 and the PI3K inhibitor BKM120, and blocking of the STAT6/NFAT signaling in TAMs using the STAT6 inhibitor AS1517499 and the NFAT-calcineurin inhibitor FK506, resensitize GBM to BLZ945 treatment (76).